Apertor Pharmaceuticals

Executive Summary

Apertor Pharmaceuticals is a Cambridge-based biotechnology company founded in 2019, pioneering a novel class of small molecule therapeutics called 'Interceptors.' These heterobifunctional molecular glues are designed to selectively disrupt disease-causing protein-protein interactions (PPIs) by inducing proximity with an endogenous protein, thereby blocking pathological signaling complexes. The company's proprietary platform addresses a key challenge in drug discovery—targeting PPIs, which are often undruggable with conventional small molecules. Apertor focuses on oncology and other diseases, leveraging its platform to develop first-in-class agents. As a private, early-stage company with no disclosed financing rounds or clinical pipeline, Apertor remains in the preclinical phase, working to validate its technology and advance candidates toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead Program40% success
• Q3 2026Series A or Seed Financing Announcement60% success
• Q1 2027IND-Enabling Studies Initiation30% success